Carisma Therapeutics Begins Study of CAR Macrophage Therapy for HER2-Overexpressing Solid Tumors

Big news from the Charisma Therapeutics team, co-founded by Gabrielle’s Angels grantee Dr. Saar Gill – they’ve just started the FIRST EVER clinical trial for a CAR-engineered macrophage (CAR-M) cell therapy. In preclinical trials, the treatment demonstrated the potential to overcome the challenges that have kept CAR T-cell therapies from benefitting patients with solid tumors. This treatment could be a game changer and we can’t wait to hear more! Congratulations to Dr. Gill and team! Read more here.